enGene’s (ENGN) “Market Outperform” Rating Reaffirmed at JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of enGene (NASDAQ:ENGN) in a research report sent to investors on Monday,Benzinga reports. They currently have a $18.00 price target on the stock.

Several other equities analysts have also recently weighed in on ENGN. HC Wainwright started coverage on shares of enGene in a research report on Monday. They set a “buy” rating and a $25.00 price objective on the stock. Oppenheimer reiterated an “outperform” rating and set a $30.00 price target on shares of enGene in a report on Tuesday, September 24th. Morgan Stanley reissued an “overweight” rating and issued a $40.00 price objective on shares of enGene in a research note on Wednesday, September 11th. Raymond James initiated coverage on enGene in a research note on Wednesday, November 27th. They set an “outperform” rating and a $23.00 target price on the stock. Finally, Citizens Jmp raised shares of enGene to a “strong-buy” rating in a research report on Monday, November 18th. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, enGene presently has an average rating of “Buy” and a consensus target price of $29.78.

enGene Trading Up 6.0 %

Shares of ENGN opened at $6.32 on Monday. The business’s 50-day moving average price is $8.05 and its 200 day moving average price is $7.77. The company has a current ratio of 19.52, a quick ratio of 19.52 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $279.45 million, a P/E ratio of -10.90 and a beta of -0.78. enGene has a 1-year low of $4.42 and a 1-year high of $18.40.

enGene (NASDAQ:ENGN) last released its earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.06. Analysts expect that enGene will post -1.52 earnings per share for the current year.

Insider Activity at enGene

In other news, CEO Ronald Harold Wilfred Cooper purchased 10,000 shares of the company’s stock in a transaction dated Friday, September 27th. The shares were bought at an average price of $5.70 per share, with a total value of $57,000.00. Following the completion of the transaction, the chief executive officer now directly owns 10,000 shares in the company, valued at $57,000. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Growth Opportunities F. Forbion acquired 341,332 shares of the firm’s stock in a transaction that occurred on Monday, September 30th. The shares were purchased at an average cost of $6.34 per share, with a total value of $2,164,044.88. Following the completion of the acquisition, the insider now owns 2,400,791 shares in the company, valued at $15,221,014.94. This trade represents a 16.57 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 420,965 shares of company stock valued at $2,651,103. Insiders own 13.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Wolverine Asset Management LLC acquired a new stake in shares of enGene in the third quarter valued at about $37,000. Point72 Asset Management L.P. lifted its position in shares of enGene by 1,410.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock worth $4,376,000 after purchasing an additional 619,100 shares during the last quarter. SR One Capital Management LP bought a new stake in enGene during the 2nd quarter valued at approximately $4,715,000. Franklin Resources Inc. grew its holdings in enGene by 48.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock valued at $7,854,000 after buying an additional 389,918 shares during the last quarter. Finally, Logos Global Management LP increased its position in enGene by 50.0% in the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after buying an additional 400,000 shares during the period. Institutional investors own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.